Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SCTV02
- Development stage
- Phase 2
- Lead developer
- Sinocelltech
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
SCTV02 is a recombinant protein vaccine developed for the prevention of diseases caused by respiratory syncytial virus (RSV) infection. RSV is a major cause of lower respiratory tract infections such as bronchiolitis and pneumonia in infants, and upper respiratory tract infections in older children and adults. SCTV02 is being evaluated in clinical trials for its safety, tolerability, and immunogenicity in healthy adults. The vaccine is being developed by Sinocelltech Group and has received approval to begin Phase 1/2 clinical trials in China[1][2][3].
Beyond the preview
Go deeper on SCTV02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SCTV02.